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Distinct CD1d docking strategies exhibited
by diverse Type II NKT cell receptors
Catarina F. Almeida1,2,8, Srinivasan Sundararaj3,8, Jérôme Le Nours3,4,8, T. Praveena3,4, Benjamin Cao5,
Satvika Burugupalli5, Dylan G.M. Smith5, Onisha Patel3, Manfred Brigl6, Daniel G. Pellicci1,2,
Spencer J. Williams 2,5, Adam P. Uldrich1,2,9*, Dale I. Godfrey 1,2,9* & Jamie Rossjohn 3,4,7,9*
Type I and type II natural killer T (NKT) cells are restricted to the lipid antigen-presenting
molecule CD1d. While we have an understanding of the antigen reactivity and function of
type I NKT cells, our knowledge of type II NKT cells in health and disease remains unclear.
Here we describe a population of type II NKT cells that recognise and respond to the
microbial antigen, α-glucuronosyl-diacylglycerol (α-GlcADAG) presented by CD1d, but not
the prototypical type I NKT cell agonist, α-galactosylceramide. Surprisingly, the crystal
structure of a type II NKT TCR-CD1d-α-GlcADAG complex reveals a CD1d F’-pocket-docking
mode that contrasts sharply with the previously determined A’-roof positioning of a sulfatide-
reactive type II NKT TCR. Our data also suggest that diverse type II NKT TCRs directed
against distinct microbial or mammalian lipid antigens adopt multiple recognition strategies
on CD1d, thereby maximising the potential for type II NKT cells to detect different lipid
antigens.
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Natural killer T (NKT) cells recognise lipid-based antigens(Ag) presented by the major histocompatibility class I(MHC I)-like molecule CD1d (reviewed in ref. 1). There
are two broad classes of NKT cells, deﬁned as type I and type II
NKT cells. The most extensively studied are the type I NKT cells,
which express an invariant TCR α-chain (Vα14-J18 in mice,
Vα24-Jα18 in humans and strongly respond to the glycolipid α-
galactosylceramide (α-GalCer)) (reviewed in ref. 1). Upon acti-
vation, type I NKT cells rapidly produce an array of cytokines and
are implicated in a broad range of diseases through their ability to
modulate Ag-presenting cells and effector T, B and natural killer
(NK) lymphocytes (reviewed in ref. 1). Type II NKT cells are also
CD1d restricted, but they are distinguished from type I NKT cells
because they neither express the invariant TCR α-chain that
characterises type I NKT cells nor do they recognise α-GalCer
(reviewed in refs. 1,2). The speciﬁcity and function of type II
NKT cells is poorly understood although some evidence suggests
that they play an immunosuppressive role that may oppose the
function of type I NKT cells3,4 (and reviewed in refs. 1,2). Given
that type II NKT cells appear to be more abundant in humans
than their type I NKT cell counterparts5–7 (and reviewed in
ref. 8), it is important to understand the molecular mechanisms
underpinning their antigen reactivity and speciﬁcity.
The availability of α-GalCer and CD1d–α-GalCer tetramers9
has facilitated the study of type I NKT cells and the development,
functional potential, and molecular basis for Ag-recognition by
these cells is now well understood (reviewed in ref. 1). Conversely,
a limited understanding of the Ags recognised by type II
NKT cells has hampered the study of these cells, although some
studies have identiﬁed Ags recognised by some type II NKT cell
lines, including sulfatide, β-glucosylceramide (β-GlcCer), phos-
phatidylglycerol (PG), diphosphatidylglycerol (DPG), lysopho-
sphatidylcholine (LPC) and lysophosphatidylethanolamine
(LPE)10–20. Structural studies have determined how a type II
NKT TCR can bind to sulfatide or lysosulfatide presented by
mouse CD1d21,22, and revealed a docking mode that was distinct
to the type I NKT TCR–CD1d–α-GalCer interaction (reviewed in
ref. 23). Namely, type I NKT TCRs bind with a parallel docking
mode over the F′-pocket of CD1d, with the TCR α-chain dom-
inating the interaction with the galactose headgroup, while the
TCR β-chain binds solely to CD1d (reviewed in ref. 23). In con-
trast, the sulfatide-reactive type II NKT TCR docked orthogonally
over the A′-pocket of CD1d with only the CDR3β loop inter-
acting with the sulfatide headgroup21,22. These studies suggests
that the structural and molecular basis for CD1d–Ag recognition
between type I and type II NKT cells is fundamentally distinct
(reviewed in refs. 1,24). However, it remains to be determined
whether this represents a general dichotomy that distinguishes
the mode of Ag recognition by type I and type II NKT cells. We
previously identiﬁed an atypical population of CD1d-restricted
NKT cells that utilise a Vα10Jα50 TCR α-chain that recognise
α-GalCer and α-GlcCer. Some of these atypical NKT cells were
activated by a mycobacterial Ag, α-glucuronosyl-diacylglycerol
(α-GlcADAG)25 presented by CD1d.
Here, using α-GlcADAG-loaded CD1d tetramers, we char-
acterise a population of type II NKT cells that are selectively
reactive to the α-GlcADAG Ag presented by CD1d and do not
recognise α-GalCer. Using a panel of synthetic α-GlcADAG
analogues, we demonstrate the key moieties of this molecule that
facilitate type II NKT TCR recognition. Structural analysis of a
type II Vβ8.2+ NKT TCR–CD1d–α-GlcADAG complex revealed
a parallel docking mode over the F′-pocket of CD1d, which
contrasted the type II NKT TCR–CD1d–sulfatide ternary com-
plexes21,22. Extensive CD1d mutational analysis against a panel of
diverse self and microbial-antigen-reactive type II NKT TCRs
reveal that type II NKT cell TCRs can adopt differing docking
strategies to engage speciﬁc CD1d–Ag complexes. Thus, this
study deﬁnes how a microbial-Ag is recognised by a type II NKT
TCR, and demonstrates that type II NKT TCRs can bind with
diverse docking modes to CD1d–Ag. This highlights the diverse
lipid-based Ag recognition by type II NKT TCRs.
Results
Identiﬁcation of CD1d–α-GlcADAG tetramer+ NKT cells. We
previously characterised a population of α-GlcADAG-reactive
NKT cells, but the extent to which NKT cells can recognise this
microbial Ag was unknown25. To speciﬁcally identify α-
GlcADAG-reactive NKT cells, NKT cells were ﬁrst enriched by
depletion of immature (CD24+) thymocytes25, and CD1d–α-
GlcADAG tetramers were used to stain mouse thymocytes from
wildtype (wt), Jα18−/− and CD1d−/− mice in a BALB/c back-
ground (Fig. 1a, Supplementary Fig. 1a). Both CD1d–α-GlcA-
DAG and CD1d–α-GalCer tetramers identiﬁed populations from
both wt and Jα18−/− BALB/c thymus but not in the CD1d−/−
BALB/c thymus (Fig. 1a, Supplementary Fig. 1a), indicating that
the populations of tetramer+ cells in both cases were CD1d-
dependent. As expected, CD1d–α-GalCer tetramers labelled a
clear population of T cells in Jα18−/− mice, albeit much less
abundant than their counterparts in wt mice25. While CD1d–α-
GlcADAG tetramer+ cells were less abundant than CD1d–α-
GalCer tetramer+ cells, they were still clearly detected in both
wt and Jα18−/− BALB/c thymus and there was a high
statistical signiﬁcance when comparing these cells in Jα18−/−
versus CD1d−/− thymus (Fig. 1a).
To determine if the NKT cells identiﬁed by CD1d–α-
GlcADAG tetramers were distinct from CD1d–α-GalCer-reactive
cells, BALB/c thymus samples were co-stained with both
CD1d–Ag tetramers using different coloured ﬂuorochromes.
Although most wt-derived thymocytes identiﬁed by CD1d–α-
GlcADAG tetramers co-stained with CD1d–α-GalCer tetramers,
a subset of these NKT cells did not (Fig. 1b, Supplementary
Fig. 1a). This was very clear in Jα18−/− thymus, where 50% of the
CD1d–α-GlcADAG tetramer+ cells did not bind the CD1d–α-
GalCer tetramer. Similar to CD1d–α-GalCer-reactive type I
NKT cells, the CD1d–α-GlcADAG tetramer+ NKT cells included
two main subsets, namely CD4+ or CD4−CD8− double negative
(DN) (Fig. 1c) although the ratio of these varied between
mice and in some instances, CD4−CD8+ cells were also detected.
Reminiscent of type I NKT cells, CD1d–α-GlcADAG tetramer+
cells expressed the activation/memory markers CD44 and
CD69 (Fig. 1c). Collectively, these data show that CD1d–α-
GlcADAG tetramer+ cells include a mixture of type I and type II
NKT cells.
Diverse CD1d–α-GlcADAG tetramer+ NKT TCRs. We next
determined the TCR sequences used by the CD1d–α-GlcADAG
tetramer+ cells that were sorted as single cells from both wt and
Jα18−/− BALB/c thymi, following tetramer-associated magnetic
enrichment (TAME) based on gates depicted in Fig. 1d and
Supplementary Fig. 1b. CD1d–α-GalCer+ CD1d–α-GlcADAG
tetramer− type I NKT cells from wt mice were also sorted as
controls. Single cell TCR α- and TCR β-chain paired analysis was
performed using multiplex PCR, as previously described26 (Sup-
plementary Table 1). CD1d–α-GalCer tetramer+ cells are known
to express the canonical Vα14Jα18+ type I NKT TCR α-chain
rearrangement27. In contrast, approximately half (12 out of 25
paired TCR sequences) of the CD1d–α-GlcADAG tetramer+
sorted cells expressed Vα10Jα50 TCR α-chain rearrangements,
similar to the Vα10+ NKT cells present in Jα18−/− mice that we
previously described25. Interestingly, four CD1d–α-GlcADAG
tetramer+ clones from wt BALB/c mice expressed a TCR α-chain
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in which the Jα50 gene was rearranged with Vα15, Vα4, Vα11, or
Vα4.4, instead of the Vα10 gene. These TCR α-chains displayed
little or no homology in their CDR1α and CDR2α regions, yet
possessed highly similar CDR3α regions suggesting that the Jα50-
encoded region confers CD1d–α-GlcADAG recognition in the
context of different Vα gene usage. This may be due to the
conservation of the CDR3α residues Ser109, Ser110 and Phe113
in each of these TCRs, three residues that were involved in the
recognition of CD1d–α-GlcCer complexes by Vα10Jα50+ NKT
TCRs25. The different CDR1α and CDR2α loops may also facil-
itate CD1d binding in different ways. Indeed, in a previous study
we demonstrated that a Vα10Jα50+ NKT TCR utilised residues
within the CDR1 and CDR2 loops to establish contact with
CD1d, whilst conserved CDR3α residues contacted both CD1d
and the antigen25. Interestingly two unique TCR α-chain
sequences that did not express Vα14, Jα18 or Jα50 gene
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Fig. 1 Identiﬁcation of CD1d–α-GlcADAG tetramer+ NKT cells in mice. Flow cytometry analysis of anti-CD24-depleted thymocytes from BALB/c wt, Jα18−/− or
CD1d−/− mice a. On the left, representative plots showing αβTCR versus CD1d–α-GalCer tetramer (top) or CD1d–α-GlcADAG tetramer staining (bottom) on
gated 7AAD−B220−CD11c−CD11b− thymocytes. Numbers next to outlined areas indicate percent cells in each gated population. Graphs on the right show the
frequency and total cell numbers per whole thymus, of the population identiﬁed by the gate in each plot. Values are representative of a total of n= 7 individual
experiments where in 5 (out of 7) experiments each black dot represents a pool of ﬁve mice (Exps. #1 and #2) or three mice (Exps. #3–5) thymi per group
and in 2 (out of 7) experiments the grey dots represent individual thymi. **p=0.0079, ****p < 0.0001 determined by the two tailed Mann–Whitney U test.
b Representative plots of dual tetramer labelling of gated BALB/c thymocytes, showing CD1d–α-GlcADAG tetramer versus CD1d–α-GalCer tetramers on
7AAD−B220−CD11c−CD11b−αβTCRint/hi cells. c CD4 versus CD8 expression (top), and CD44 versus CD69 (bottom) for each population that has been
segregated based on CD1d–α-GlcADAG versus CD1d–α-GalCer tetramer gates in b. Plots are derived from four concatenated ﬂow cytometry ﬁles acquired in a
single experiment, where each ﬁle corresponds to a pool of four thymii (representative of two independent experiments). d Representative ﬂow cytometry plots
showing CD1d–α-GalCer versus CD1d–α-GlcADAG tetramer staining in both pre-enriched and post-enriched samples following CD1d–α-GlcADAG tetramer-
associated magnetic enrichment (TAME). Plots depict gated 7AAD−B220−CD11c−CD11b−αβTCRint/hi thymocytes. Numbers indicate percent cells in each
gated population. Cells from each population (as identiﬁed by gates) were individually sorted into individual wells for TCR gene PCR ampliﬁcation. In total three
independent sorting experiments were performed, where experiments contained a pool of ﬁve mice (Exps. #1 and #2) or three mice (Exp. #3), respectively
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segments (Vα4Jα17, Vα8Jα49) were also identiﬁed amongst wt
thymocytes sorted with CD1d–α-GlcADAG tetramers (Supple-
mentary Table 1). TCRβ sequence analysis indicated diversity
within the composition and length of the CDR3β regions
amongst all sorted populations, and they almost exclusively used
Vβ8 (24 out of 25 paired TCR sequences), consistent with pre-
dominant Vβ8 gene usage within type I NKT cells9, Vα10Jα50+
NKT cells25, and type II NKT cells28. Some TCR sequences with
identical TCRα and TCRβ nucleotide homology were identiﬁed in
independently sorted cells (Supplementary Table 1), suggesting
clonal expansion in vivo.
Similar results were obtained when NKT cells were isolated
from Jα18−/− BALB/c mice (Supplementary Table 1). In the
absence of Jα18, Vα10Jα50 TCRs were prominent within the
population that stained with CD1d–α-GlcADAG tetramers (5 out
of 11 paired TCR sequences), and all used the Vβ8 gene. Five
unique TCR α-chain sequences that did not express Vα14, Vα10
or Jα50 gene segments (Vα11Jα9, Vα5Jα12, Vα3Jα4, Vα17Jα2,
Vα8Jα16) were observed amongst Jα18−/− thymocytes sorted
with CD1d–α-GlcADAG tetramers (Supplementary Table 1).
Interestingly, the Vα11Jα9-Vβ8.2 TCR (designated clone name:
A11B8.2) was detected in 12 out of 16 sorted clones. As these
NKT TCRs displayed non-germline-encoded residues in both the
CDR3α and CDR3β regions, this suggests that these T cells had
expanded in vivo prior to their isolation.
Overall, the population of thymocytes identiﬁed by CD1d–α-
GlcADAG tetramers was characterised by heterogeneous TCR
usage in both Jα18−/− and wt BALB/c mice, with a range of TCR
α-chain sequences and an almost exclusive use of the Vβ8 chain.
Moreover, these results demonstrate a means by which microbial
Ag-speciﬁc type II NKT cells can be isolated.
Speciﬁcity of the CD1d–α-GlcADAG tetramer+ T cells. A
selection of TCR sequences from CD1d–α-GlcADAG tetramer+
NKT cells were used to generate TCR-transduced BW58 cell lines
to validate their CD1d–α-GlcADAG reactivity. These included
two type II NKT TCRs: Vα11Jα9-Vβ8.2 TCR (clone A11B8.2)
and a Vα17Jα2-Vβ8.2 TCR (clone A17B8.2) from Jα18−/− thy-
mus (Supplementary Table 1) and two atypical NKT TCRs:
Vα10Jα50-Vβ8.2 TCR and Vα10Jα50-Vβ8.3 (clone A10B8.2 and
A10B8.3 from wt thymus (Supplementary Table 1). Controls
included BW58 cell lines transduced with: CD1d-sulfatide-
reactive XV19 type II NKT TCR29; a canonical type I NKT
TCR (VB8-STD); and an atypical NKT TCR (Vα10Jα50-Vβ8.1
TCR, clone A10B8.1)25.
The transduced cell lines were tested for reactivity with CD1d
tetramers loaded with a selection of lipid Ags. The Vα10Jα50-
Vβ8.2+ and Vα10Jα50-Vβ8.3+ atypical NKT clones (A10B8.2
and A10B8.3) were labelled by CD1d–α-GlcADAG tetramers, but
not by CD1d–sulfatide or CD1d tetramers carrying endogenous
lipid Ags (CD1d-endo) tetramers, although CD1d–α-GalCer
tetramers stained with greater intensity (~25× and 12× higher
than α-GlcADAG, respectively, based on tetramer MFI) (Fig. 2a,
Supplementary Fig. 1c). Thus, the clones A10B8.2 and A10B8.3
represent examples of atypical NKT TCRs that do not utilise the
canonical type I NKT TCR Vα14Jα18 α-chain rearrangement but
can still recognise α-GalCer-loaded CD1d25,30, similar to the
control clone A10B8.125. Interestingly, A10B8.1 atypical
NKT cells did not label with α-GlcADAG-loaded CD1d tetramers
suggesting that the TCR β-chain modulates the differential
recognition and Ag-speciﬁcity amongst atypical NKT cells, akin
to type I NKT cells31,32.
As expected, the XV19 type II NKT TCR+ cell line showed
clear staining with sulfatide-loaded CD1d tetramer whereas the
other CD1d tetramers did not stain these cells at higher levels
than CD1d–endo (Fig. 2a). The VB8-STD type I NKT TCR+ cell
line was stained by CD1d–α-GlcADAG tetramer with an intensity
that was between CD1d–endo tetramer and CD1d–α-GalCer
tetramers (Fig. 2a). This shows that some type I NKT cell clones
can recognise the microbial Ag α-GlcADAG in the context of
CD1d, consistent with the detection of a subset of type I
NKT cells by CD1d–α-GlcADAG tetramer (Fig. 1c, d) and the
presence of Vα14Jα18 rearrangements amongst cells that co-
stained with CD1d–α-GlcADAG and CD1d–α-GalCer tetramers
(Supplementary Table 1).
Of particular interest, the type II NKT cell-derived Vα11Jα9-
Vβ8.2 TCR+ line (A11B8.2) was clearly labelled by CD1d–α-
GlcADAG tetramer (~20× higher than CD1-endo tetramer MFI).
In contrast, CD1d–α-GalCer tetramer or CD1d–sulfatide tetra-
mers failed to provide staining of this cell line above CD1d–endo
tetramers, highlighting that α-GlcADAG is indeed the preferred
ligand for the A11B8.2 TCR (Fig. 2a). The type II NKT TCR+
cell-derived A17B8.2 clone also preferentially bound to α-
GlcADAG-loaded CD1d tetramers above CD1d-endo tetramers
(~1.5× higher based on tetramer MFI), and interestingly,
sulfatide-loaded and α-GalCer-loaded CD1d tetramers displayed
a lower ability to stain this line when compared to CD1d-endo
tetramers (~2× and 9×, respectively), suggesting that they can act
as weaker lipid-antigens for this clone (Fig. 2a).
Collectively, these results highlight the existence of diverse
NKT cells expressing TCRs that can interact with CD1d–α-
GlcADAG including subsets of type I, type II, and atypical
NKT cells.
CD1d–α-GlcADAG complexes can activate NKT TCR+ cells.
Plate bound CD1d-lipid Ag activation assays were carried out to
investigate if the TCR+ cell lines could respond to CD1d–α-
GlcADAG recognition (Fig. 2b). The A11B8.2 type II, the
A10B8.2 atypical, the A10B8.3 TCR+ atypical, and the VB8-STD
type I NKT TCR+ cell lines, were activated by α-GlcADAG-
loaded CD1d, leading to CD69 up-regulation and IL-2 produc-
tion at levels above those elicited by CD1d-endo. Consistent with
the tetramer staining (Fig. 2a) the A10B8.2, A10B8.3 atypical
NKT TCR+ and the controls A10B8.1 atypical NKT TCR+ and
VB8-STD type I NKT TCR+ cell lines responded more strongly
to stimulation with CD1d-α-GalCer, while this induced only a
weak response from A11B8.2 and A17B8.2 type II NKT TCR+
cells. Notably, and in contrast to A11B8.2, A17B8.2, or VB8-STD
NKT TCR lines, no response was detected by the A10B8.1,
A10B8.2, and A10B8.3 atypical NKT TCR+ cell line following
stimulation with CD1d-endo, implying that these TCRs are
highly Ag-dependent (Fig. 2b). Thus, CD1d–α-GlcADAG is
capable of stimulating cells expressing both classical type I, type
II, and atypical NKT TCRs, in an Ag-dependent manner. This
provides the ﬁrst example of a microbial Ag that can stimulate all
three classes of NKT cells.
TCR–CD1d–Ag-binding afﬁnity. To understand the speciﬁc
recognition of CD1d–Ag by type II and atypical NKT TCRs, we
measured the binding afﬁnity of soluble forms of the A11B8.2 and
A10B8.2 TCRs to CD1d–α-GlcADAG, CD1d–α-GalCer, or
CD1d-endo using surface plasmon resonance (SPR). The
A10B8.2 atypical NKT TCR bound weakly to CD1d–α-GlcADAG
(with a dissociation constant (Kd) of ~40 μM), whereas this TCR
displayed stronger binding to α-GalCer-loaded CD1d, with a Kd
of 11.4 μM, but was not reactive to CD1d-endo (Kd > 150 μM)
(Fig. 2c), consistent with the lack of CD1d-endo tetramer staining
or activation results depicted in Fig. 2a, b. The type II NKT TCR
(A11B8.2) bound to CD1d–α-GlcADAG with Kd value of
14.6 μM, which was ~2-fold higher afﬁnity than that observed for
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CD1d-endo (Kd= 33.4 μM). Binding of this TCR to CD1d–α-
GalCer could also be detected, although with a much lower afﬁ-
nity (Kd= 66.5 μM) (Fig. 2c). Notably, while binding values can
be measured in SPR, differences in binding afﬁnity may reduce
the binding threshold that contributes to the lack of tetramer
staining detection by ﬂow cytometry. Accordingly, this SPR
analysis supports our observations that the A11B8.2 and A10B8.2
TCRs interact with α-GlcADAG presented by CD1d, and more-
over, that A11B8.2 preferentially recognises this Ag over the
prototypic NKT cell Ag α-GalCer.
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Fine speciﬁcity of α-GlcADAG-reactive TCRs. The ﬁne speci-
ﬁcity of CD1d–α-GlcADAG-reactive TCRs was examined using
CD1d tetramers loaded with a range of synthetic α-GlcADAG
variants (Fig. 3a). These included the (R-C19:0/C16:0) analogue
bearing R-tuberculostearic acid (R-TBSA) (C19:0) at sn-1 and
C16:0 at sn-2 that is expressed by Mycobacterium smegmatis25
(used in Figs. 1–6), along with two synthetic analogues: the
regioisomer GlcADAG (R-C16:0/C19:0) bearing R-TBSA at sn-2
and C16:0 at sn-1; and (C18:0/C16:0) that lacks the distinguishing
methyl branch of TBSA (Supplementary Fig. 1). In addition, we
included a panel of established NKT cell Ags: α-GalCer (C20:2);
α-glucuronosylceramide (α-GlcACer C14:0, GSL-1) and α-
galacturonosylceramide (α-GalACer C14:0, GSL-1′), both ori-
ginally from Sphingomonas spp.33,34 and both contain uronic acid
head groups, similar to α-GlcADAG; α-glucosyldiacylglycerol (α-
GlcDAG C16:0/C18:1 containing vaccenic acid) originally from
Streptococcus pneumoniae35; α-galactosyldiacylglycerol (α-Gal-
DAG C17:1/C16:0) originally from Borrelia burgdorferi36;
α-GlcCer (C20:2)37,38; the β-linked Ags sulfatide C24:115 and
GD3 C26:039.
The control VB8-STD type I NKT TCR+ cell line and XV19
type II NKT TCR+ cell lines showed the expected patterns of
reactivity, with strong binding to CD1d tetramers loaded with α-
GalCer for the former, and sulfatide for the latter (Fig. 3a).
Moderate binding by CD1d tetramers loaded with α-GlcADAG
R-C19:0/C16:0, but not the other variants of this Ag, as well as
to other microbial-derived α-linked glycolipids (α-GlcADAG,
α-GalACer, α-GlcDAG, and α-GlcCer), was observed for the
VB8-STD type I NKT TCR+ cell line, consistent with previous
reports33–36.
For the A11B8.2 type II NKT TCR+ cell line, of the
α-GlcADAG variants, only the bona ﬁde mycobacterial species
(R-C19:0/C16:0) was clearly bound by the TCR at levels greater
than CD1d-endo (Fig. 3a). This type II NKT cell line showed no
binding to any of the other CD1d tetramer–Ag complexes, which
highlights the ﬁne speciﬁcity of this type II NKT cell-derived
TCR, and also the importance of both the polar head group and
the acyl chain composition and regioselectivity for recognition of
this Ag. In contrast, the A10B8.2 atypical NKT TCR+ cell line
bound to CD1d tetramers loaded with α-GlcADAG R-C19:0/
C16:0 and R-C16:0/C19:0 analogues, but not to the C18:0/C16:0
analogue (Fig. 3a). As expected25, this atypical NKT cell line
stained strongly with both α-GalCer and α-GlcCer-loaded CD1d
tetramers and also showed moderate binding to α-GlcDAG from
S. pneumoniae and both the Sphingomonas-derived lipids α-
GlcACer and α-GalACer (Fig. 3a). This cell line showed no
appreciable binding to tetramers loaded with sulfatide, GD3 or
‘endo’.
We investigated more analogues of α-GlcADAG including a
C18:1/C16:0 variant that has been isolated from M. smegmatis
and Corynebacterium glutamicum, in which the TBSA is replaced
by oleic acid bearing a double bond between C9 and C1040–43
(Supplementary Fig. 2 and Fig. 3b). This is representative of
related compounds that have been isolated from the pathogenic
fungus Aspergillus fumigatus44. We also synthesised and inves-
tigated analogues with R- or S- versions of TBSA and oleic
acid-containing α-GlcADAG or α-GlcDAGs, which lack the
glucuronic acid on their glycosidic headgroup (Supplementary
Fig. 2 and Fig. 3b). The strongest staining of the type II A11B8.2
NKT TCR+ cell line was achieved with CD1d tetramers loaded
with the α-GlcADAG variant bearing the R-TBSA chain
(R-C19:0/C16:0). Moderate staining of this line was achieved by
the oleic-acid (C18:1/C16:0) followed by the S-TBSA variant
(S-C19:0/C16:0), and to a much lower degree by the ‘isooleoyl’
regioisomer α-GlcADAG (C16:0/C18:1) (Fig. 3b). Furthermore,
IL-2 was produced in response to plate-bound CD1d loaded with
R- and S-TBSA variants of C19:0/C16:0, C18:1/C16:0 or C16:0/
C18:1 α-GlcADAGs (Fig. 3b), which demonstrates that these
variants can also elicit functional responses of type II NKT cells.
Notably, none of the variants lacking the uronic acid on the
glycosidic group was able to elicit responses by the A11B8.2 NKT
TCR+ cell line nor allow CD1d-tetramer staining, highlighting a
high degree of speciﬁcity of the A11B8.2 TCR towards the
glucuronic acid. These experiments show that the A11B8.2 TCR
has the ability to recognise and respond to α-GlcADAG Ags not
only from M. smegmatis but also other α-glucuronosyl-producing
species, such as those in C. glutamicum and A. fumigatus.
Overview of the A11B8.2 TCR–CD1d–α-GlcADAG ternary
complex. To gain insight into the mode of recognition of the
A11B8.2 TCR for CD1d presenting a microbial α-linked glyco-
lipid Ag; we determined the crystal structure of the unligated
TCR and the A11B8.2 TCR–CD1d–α-GlcADAG ternary complex
to 1.7 and 3.0 Å resolution, respectively (Supplementary Table 2).
The electron density at the A11B8.2 TCR–CD1d interface was
unambiguous and unbiased electron density was clearly visible for
the headgroup of α-GlcADAG (Supplementary Fig. 3a). The
docking strategy adopted by the A11B8.2 NKT TCR was in clear
contrast to the orthogonal docking mode of the type II XV19
TCR atop of the CD1d–sulfatide complex (docking angle ~100°)
(Fig. 4a–c, Supplementary Fig. 3b)21,22. Instead, and reminiscent
of the classical type I and atypical NKT TCR–CD1d–Ag ternary
complexes (Fig. 4a, b), the A11B8.2 TCR docked parallel over the
F′-pocket of the CD1d Ag-binding cleft (docking angle ~15°)
(Fig. 4b and Supplementary Fig. 3b). However, unlike the type I
NKT TCR–CD1d–Ag ternary complex, and more analogous to
the atypical Vα10+ TCR–CD1d–α-GlcCer ternary complex25, the
individual A11B8.2 TCR α- and β-chains was positioned more
towards the α2-helix and F′-pocket of CD1d (Supplementary
Fig. 3b). Upon A11B8.2 TCR–CD1d–Ag complex formation, the
buried surface area (BSA) was ≈1000 Å2 (Fig. 4c) similar to the
reported BSA of the type I (760–860 Å2) and Vα10 (910 Å2) NKT
TCRs. Here, the A11B8.2 TCR α- and β-chains contributed to
57% and 43% of the BSA, respectively. The CDR3α (24% BSA)
and CDR3β (24% BSA) loops contributed the most to the TCR
A11B8.2–CD1d–Ag interface and to a lesser extent, the CDR1α
(13.5% BSA), CDR2α (9% BSA), and CDR2β (9% BSA) loops were
also involved in the interaction with CD1d–α-GlcADAG
Fig. 2 Antigen reactivity of CD1d–α-GlcADAG tetramer+ sorted clones. a α-GlcADAG-, α-GalCer-, sulfatide-loaded or unloaded CD1d (CD1d-Endo)
tetramer reactivity of BW58 cells expressing the nominated NKT cell TCRs. Representative plots from n= 5 experiments. Numbers depict mean
ﬂuorescence intensity (MFI) of CD1d tetramer within the gate encompassing 7AAD− cells with equivalent surface αβTCR levels). b CD69 induction and IL-
2 production from NKT TCR+ BW58 cell lines shown in a, following culture with immobilised CD1d–α-GlcADAG, CD1d–α-GalCer or CD1d–endo for 16 h.
Graphs depict the mean CD69 fold difference relative to unstimulated control condition (top), or IL-2 detection in the supernatant (bottom). Error bars
depict SEM. When CD1d was used at 10 μg/mL. Data is representative from n= 4 (n= 5 for A11B8.2) independent experiments. c SPR afﬁnity
measurement of soluble A11B8.2 and A10B8.2 NKT TCRs to CD1d–endo and CD1d loaded with α-GlcADAG and α-GalCer. The equilibrium curves are
representative of one experiment performed in duplicate. Error bars refer to SEM of two replicates. The sensorgrams are representative of one experiment.
Kd values are derived from duplicate runs from n= 3 (i) and n= 2 (ii) independent experiments performed
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(Supplementary Table 3). Overall, the F′-pocket footprint of the
α-GlcADAG-reactive type II NKT TCR ternary complex described
here contrasted markedly with the previously determined A′-roof
centric docking of the sulfatide-reactive type II NKT TCR.
Type II NKT TCR/CD1d–α-GlcADAG interactions. The cen-
trally positioned CDR1α loop mediated contacts with both α1-
and α2-helices of CD1d, whereby Lys31α intersected both helices
by forming a salt bridge with Asp80 and van der Waals (vdw)
contacts with Asp153 (Fig. 5a), while Thr29α interacted with
Val72 of CD1d. The CDR2α loop was positioned directly
above the α2-helix of CD1d, in which Ala51α and Gln52α con-
tacted solely Gln154 via vdw and hydrogen bond interactions,
respectively (Fig. 5a). The CDR3α loop sat atop the α1-helix
of CD1d enabling the aromatic ring of Tyr95α to plunge into a
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hydrophobic pocket lined by Leu84, Val149, and Leu150 (Fig. 5a).
Further, Met93α and Gly94α from the CDR3α loop contributed
to the interface by contacting Val75, Ser76, Arg79, Asp80,
and Glu83 via vdw contacts (Fig. 5a). Within the TCR β-chain,
the CDR2β and CDR3β loops dominated the interactions at
the interface. Here, the CDR2β loop sat peripherally above the
α1-helix of CD1d, whereby Tyr50β contacted the side chains of
Met87 and Glu83, while the adjacent framework residues Tyr48β
and Glu56β also made contacts with Lys86 and Glu83 or Lys86
and Arg21 (respectively) (Fig. 5b, Supplementary Table 3).
Notably, the Vβ8.2 in the type I NKT TCR contains equivalent
tyrosine residues in the CDR2β loop (Tyr48β and Tyr50β) that
contacted similar residues in CD1d31. Further, the CDR3β loop
reached across the external side of the CD1d cleft whereby resi-
dues Pro96β, Gln97β, Val99β, Ser100β, Tyr101β interacted
exclusively with the α2-helix (Leu145, Lys148, Val149, Ala152,
and Asp153) (Fig. 5b). The aromatic moiety of Tyr101β pointed
towards the CD1d cleft to form hydrogen bonds with the main
chain of Val149 and Ala152 (Fig. 5b). Accordingly, the non-
germline-encoded CDR3 loops dominated the interactions at the
A11B8.2 TCR/CD1d–α-GlcADAG interface (Figs. 4c, 5a, b). This
CDR3 loop-mediated dominance at the CD1d–Ag interface was
reminiscent of the type II NKT TCR–CD1d–sulfatide com-
plex21,22 and thus in clear contrast to the type I NKT
TCR–CD1d–Ag complex, which is dominated by the germline
encoded CDR1α and CDR2β loops and the invariant CDR3α loop
(Fig. 4c)31. Collectively, the structure of the type II A11B8.2 NKT
TCR–CD1d–α-GlcADAG ternary possessed features that were
markedly distinct from the type I and type II NKT
TCR–CD1d–Ag complexes that were previously characterised
structurally.
Altered headgroup position of α-GlcADAG within CD1d. The
palmitoyl (sn2) and R-TBSA (sn1) chains were positioned within
the A′-pocket and F′-pocket, respectively. However, the palmitoyl
tail adopted the unusual counter-clockwise orientation that has
been previously observed in the type I NKT TCR–CD1d–α-
Gal–GSL (PDB code: 3O8X)45 and CD1d–α-GlcDAG-s2 (PDB
code: 3T1F)35 crystal structures (Fig. 5c). While the overall
position of the headgroups of α-GalCer and other microbial-
derived Ags (α-Gal–GSL, BbGl2c and α-GlcDAG-s2) generally
lays ﬂat in the central region of the Ag-binding groove
(Fig. 5c)23,24,46–48, the α-GlcADAG carbohydrate headgroup
clearly leaned markedly towards the A′-pocket of CD1d (Fig. 5d).
Here, the glucuronosyl moiety interacted with His68, Met69,
Val72, Gly155 of CD1d via vdw contacts, whilst Thr159
formed hydrogen bonds with the 2′- and 3′-hydroxyl (Fig. 5e,
Supplementary Table 3). The TCR–α-GlcADAG interactions
were exclusively mediated by the TCR α-chain, namely, the
germline-encoded residues within the CDR1α region (Thr29α
and Lys31α), and the framework residue Lys67α (Fig. 5f).
Here, Lys31α hydrogen bonded to the carbonyl of the stearoyl
chain, whilst Thr29α interacted via vdw contacts with the
α-GlcADAG carbohydrate moiety. The positioning of the
A11B8.2 TCR α-chain indicated that the CDR1α loop would
sterically clash with the headgroups of a number of CD1d lipid
Ags, including α-GalCer, sulfatide and microbial-derived ligands,
consistent with the lack of staining of the A11B8.2 TCR+ cell line
for CD1d tetramers loaded with such Ags (Figs. 2a and 3a).
Overall, α-GlcADAG was involved in a coordinated series of
interactions, with both CD1d and the A11B8.2 TCR, which
allowed it to acquire a unique position where the headgroup of
this ligand was tilted towards the A′-pocket of CD1d, which is
in contrast to binary and ternary complexes with other CD1d-
binding Ags. Thus, the A11B8.2 type II NKT TCR–CD1d–α-
GlcADAG ternary complex reveals a distinct mechanism of lipid
recognition and provides the ﬁrst structural insight to diverse
mechanisms of CD1d–Ag recognition amongst the type II
NKT TCRs.
Type II NKT TCRs adopt multiple CD1d-binding modes. To
more broadly investigate the docking mode of diverse type II
NKT TCRs with CD1d, we generated soluble CD1d molecules
with 18 single residue mutations across the length of the Ag-
binding cleft and tested their ability to stimulate a panel of NKT
cell lines (Fig. 6). These mutants were chosen based on the
available CD1d crystal structures, where residues selected were
solvent exposed and most did not contact the lipid antigens.
These six type II NKT cell lines exhibited diverse TCR usage and
reactivity towards self-lipids or microbial lipids, thereby provid-
ing a broad perspective on the range of CD1d-docking modes
that type II NKT TCRs could potentially employ. As a control, we
also examined impact of these mutants on a type I NKT cell line
(VB8-STD).
Consistent with previous studies, the type I NKT cell line
(VB8-STD) was impacted by the CD1d mutations: Arg79Ala,
Glu83Ala, Lys86Ala, Met87Ala, Leu145Ala and Val149Ala. These
residues are localised around the F′-pocket and mediate contacts
with the type I NKT cell TCRs (Fig. 6)31. Further, and consistent
with the crystal structure, mutational analyses indicated that
Met87, Glu83, Lys86 and Val149 were critical for CD1d–Ag
recognition by the A11B8.2 TCR (Fig. 6), and that Leu145,
Thr159 and Ala152 also played a moderate role. Thus, similar to
type I NKT TCRs, CD1d recognition by the A11B8.2 NKT TCR
appears to be highly dependent on CDR2β interactions with the
CD1d residues that comprise the “energetic hot spot”31,49,50.
Similarly, the A17B8.2 TCR+ cell line also showed an interaction
map that correlates with a docking position over the F′-pocket of
Fig. 3 Fine Ag-speciﬁcity of BW58 cell lines expressing CD1d–α-GlcADAG-reactive NKT TCRs. a BW58 cell lines expressing the A11B8.2 and A10B8.2
TCRs were tested by ﬂow cytometry for their ability to bind a panel of CD1d tetramers loaded with: Mycobacteria smegmatis natural occurring α-GlcADAG
species (R-C19:0/C16:0) and two synthetic analogue variants (C16:0/C19:0) and (C18:0/C16:0); Sphingomonas spp. α-GlcACer C14:0 (GSL-1);
Sphingomonas spp. α-GalAcer C14:0 (GSL-1′); Streptococcus pneumoniae α-GlcDAG C16:0/C18:1; Borrelia burgdorferi α-GalDAG C17:1/C16:0; α-GlcCer
C20:2; α-GalCer C:20:2; sulfatide C24:1 and GD3. CD1d-endogenous and vehicle-loaded CD1d tetramers were included as controls. The VB8-STD type I
NKT TCR+ and the XV19 type II NKT TCR+ cell lines were also included as a control. Graphs represent the mean ﬂuorescence intensity (MFI) of CD1d
tetramer staining within cells with similar TCR expression from duplicate values of n= 2 (n= 3 for A11B8.2) independent experiments and SEM. b
Synthetic versions of the naturally occurring forms of α-GlcADAG bearing a methyl group with R-enantiomer or S-enantiomer (R-C19:0/C16:0 and S-
C19:0/16:0) or the oleic version containing a double bond between C9 and C10 (C18:1/C16:0) or the isooleic variant (C16:0/C18:1), were loaded into CD1d
tetramers and assessed for their ability to stain the A11B8.2 type II NKT TCR+ cell line (left), or to induce IL-2 following 16 h culture on platebound CD1d-
lipid (right). Variants in which the glucoronic headgroup (–GlcA) was substituted for a glycosydic headgroup (–Glc) were also tested. S. pneumoniae α-
GlcDAG (SPN α-GlcDAG), α-GalCer, vehicle-loaded and endogenous-loaded CD1d tetramers were included as controls. Graph on left represents the MFI
of CD1d tetramer fold increase over CD1d-endogenous staining within cells with similar TCR expression from four independent experiments ± SEM, and
graph on right depicts the mean IL-2 production of three independent experiments ± SEM
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CD1d, similar to the A11B8.2 type II NKT TCR, with mutations
Arg79Ala, Glu83Ala, Lys86Ala, Val149Ala, Thr159Ala causing a
major reduction in activation. For the A11B8.2 and A17B8.2
TCRs, it is possible that the Thr159Ala mutation was indirectly
effecting binding by impacting on lipid loading as this residue
formed H-bonds with the α-GlcADAG headgroup (Fig. 5).
In contrast, for the type II XV19 TCR+ cell line, the CD1d
mutations that impacted on cellular activation were localised to
the A′-pocket (His68Ala, Val72Ala, Thr159Ala, Asp166Ala
and Lys65Ala, Gln62Ala, Leu170Ala, and Ser76Ala, Met162Ala)
(Fig. 6) which correlates with the contact residues identiﬁed in the
crystal complex structure of the XV19 TCR–CD1d–sulfatide21,22.
The CD1d autoreactive 14S.6, TBA7 and VII68 type II NKT
TCR+ cell lines were assessed using CD1d mutants loaded with
‘endo’ Ags (Fig. 6)10,20,51,52. For the 14S.6 TCR+ cell line, the
interaction map suggested that this TCR spanned across both the
A′- and F′-pockets, ranging from Gln62 present in the distal
A′-pocket α1-helix, to Leu145, present in the distal F′-pocket. The
interaction map generated for the TBA7 TCR (Fig. 6) revealed
binding to CD1d over the F′-pocket and closer to the α1-helix.
Lastly, the interaction map of the VII68 TCR (Fig. 6) suggested
that it bound to CD1d over the extreme F′-pocket, interacting
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with residues (Glu83, Lys86, Met87 and Val149) located in both
α1- and α2-helices.
Taken together, these data suggest that, unlike type I NKT cells,
the population of type II NKT cells can adopt diverse docking
modes of that span the length of the CD1d-binding cleft. This is
likely to reﬂect the high degree of variability in TCR usage and
lipid Ag speciﬁcity that is observed for Type II NKT cells.
Discussion
We have identiﬁed a polyclonal NKT cell population that can
recognise the microbial glycolipid α-GlcADAG presented by
CD1d. To comprehensively conﬁrm the reactivity of this NKT
cell population, we have employed a combination of techniques,
including single-cell TCR sequencing, TCR-transduced cell line
generation and stimulation, and soluble TCR generation for
biophysical and structural analysis. The α-GlcADAG used in this
study is a synthetic version of one of the most abundant cell
membrane lipids in M. smegmatis40. We also show that these cells
can respond to similar α-linked glycolipids including α-GlcAdag
from A. fumigatus and C. glutamicum, α-GlcDAG from S. pneu-
moniae and α-GlcACer from Sphingomonas species. The
α-GlcADAG-responsive cells include a small subset of classical
Vα14Jα18 type I NKT cells and a population of atypical Vα10Jα50
NKT cells. Moreover, we identify here a novel population of
α-GlcADAG-speciﬁc type II NKT cells. This highlights the
potential for overlap in the Ag speciﬁcity between these subclasses
of cells and shows that distinct NKT TCRs can adopt diverse
molecular mechanisms to interact with CD1d to recognise a
common Ag.
While several Ag-speciﬁc type II NKT cell populations have
been identiﬁed10–20, structural investigations of these TCRs
interacting with their CD1d–lipid Ag targets are limited to two
studies, both using the same, sulfatide-reactive XV19 TCRs21,22.
A striking observation from these studies was that the XV19 TCR
bound over the A′-roof, in sharp contrast to type I NKT TCRs
that invariably bind over the F′-pocket (reviewed in ref. 24). This
raised the question of whether other type II NKT TCRs would
adopt this A′-roof-binding mode with CD1d-Ag. We show that
type II NKT TCRs can also bind over the F′-pocket of CD1d.
Indeed, the structure of the type II A11B8.2 TCR–CD1d–α-
GlcADAG complex revealed that the interactions between the
two Tyr residues within the CDR2β loop with a deﬁned region
over the F′-pocket of CD1d were similar to that observed for
mouse Vβ8+ NKT TCRs23,31,53. However, analysis of the binding
footprint of a range of type II NKT TCRs with diverse TCR α-
and β-chains, indicates that some type II NKT TCRs can bind in
multiple ways to CD1d. This likely reﬂects the high TCR diversity
of type II NKT cells and can engender differing reactivities to
various CD1d-restricted Ags, including non-lipid molecules54 or
even peptides and lipo-peptides55. There are some parallels
with that in MR1-mediated immunity, whereby diversity in the
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MR1-restricted T cell repertoire can also lead to differing reac-
tivities towards metabolite-based ligands and differing docking
modes atop MR156.
In summary, we identify a new, microbial Ag-speciﬁc, popu-
lation of type II NKT cells. Our ﬁndings also suggests that a
universal potent Ag for type II NKT cells is unlikely to exist.
Rather, our understanding of type II NKT cells will be built upon
studies of individual Ag-speciﬁc subsets, such as those identiﬁed
here. Nonetheless, given that type II NKT cells may be more
abundant than type I NKT cells in humans5–7 (and reviewed in
ref. 8), and considering the unique functional roles that these cells
appear to play in the immune system (reviewed in ref. 2) these
studies are important if we are to understand the full scope of Ags
recognised by type II NKT cells and to harness the therapeutic
potential of this arm of the immune system.
Methods
Mice. BALB/c wt, BALB/c Jα18−/−, BALB/c CD1d−/− were bred and maintained
according to ethics approval from The University of Melbourne Animal Ethics
Committee, under speciﬁc pathogen-free conditions at the Biological Research
Facility at the Department of Microbiology and Immunology, The University of
Melbourne, Australia. BALB/c wt colonies were sourced from either the same
facilities, or the Animal Resources Centre (ARC; Canning Vale, WA, Australia).
CD1d−/− (CD1d1 and CD1d2 double knock-out, described in ref. 57) mice were
sourced from the Peter MacCallum Cancer Centre (Australia) and backcrossed to
BALB/c for at least 10 generations. Jα18−/− mice were originally provided by M.
Taniguchi (Chiba University Graduate School of Medicine, Japan) and backcrossed
to BALB/c for at least 10 generations.
Lymphocyte isolation. Thymocytes were isolated by grinding thymi through a
50 μM mesh or cell strainer in the presence of 2% FBS PBS. For complement-
mediated enrichment of mature thymocytes, the cell suspension was then incu-
bated with anti-CD24 (I) (clone J11d—in house production) on ice for 30 min.
Rabbit complement (GTI Diagnostics, Wisconsin, USA) and 70 μg/mL deoxyr-
ibonuclease I (DNase; Roche) were then added and allowed to incubate for another
30 min at 37 °C. Thymocytes were washed with 10% FBS/RPMI, then overlayed
onto Histopaque-1083 (Sigma), and centrifuged at 1000 × g for 10 min, with no
brake, at room temperature. Cells at the interphase were recovered, centrifuged at
350 × g for 4 min at 4 °C and washed with 2% FBS/PBS, or 10% FBS/RPMI for cell
culture. All cells were quantiﬁed in a Neubauer counting chamber (Merck), with
dead cell exclusion by trypan blue solution 0.4% (Sigma).
Flow cytometry. All antibodies were acquired from BD Biosciences unless
otherwise stated. Fluorochrome-conjugated mouse-speciﬁc antibodies include:
anti-CD3-allophycocyanin (APC) or ﬂuorescein isothiocyanate (FITC) (clone 145-
2C11), anti-TCRβ APC/FITC (clone H57-597), anti-Vβ8.1/8.2 FITC/PE (clone
MR5.2), anti-CD4 Brilliant Violet (BV)570/Paciﬁc Blue/Alexa Fluor (AF)700/
BV605 (clone RM4-5), anti-CD8α APC-Cy7 (clone 53-6.7), anti-CD11c FITC/PE-
Cy5 (clone HL3), anti-CD11b FITC/PECy5 (clone M1/70), anti-B220 APC-Cy7/
FITC/PE-Cy5 (clone 30-F11), anti-CD69 PE/APC (clone H1.2F3), and anti-CD44
FITC/AF700 (clone IM7). 7-amino-actinomycin D (7AAD) viability dye (Sigma)
was included in all ﬂow cytometry-staining panels for dead cell exclusion. Strep-
tavidin (SAV)-PE, SAV-APC, and SAV-BV421 were purchased from BD
Biosciences.
Mouse CD1d tetramers were produced in house in High Five insect cells similar
to that previously described9,53,58,59. In some assays, mouse CD1d was produced in
mammalian HEK-293S.N acetylglucosaminyltransferase-I−(GnTI−) (maintained
in house > 10 years) cells by cotransfection with pHLsec vectors encoding truncated
mouse CD1d ectodomain with a C-terminal biotinylation motif and His6-tag
(amino acid sequence at the C-terminus: GSGLNDIFEAQKIEWHEHHHHHH)
and β2-microglobulin, using polyethylenimine essentially as described60. CD1d was
puriﬁed from culture supernatant by immobilised metal-afﬁnity chromatography
and size-exclusion chromatography, followed by enzymatic biotinylation using
biotin ligase (produced in-house), and further puriﬁcation by size-exclusion
chromatography, followed by storage at −80 °C.
Cell suspensions were ﬁrst incubated for 10 min on ice with Fc-receptor block
(anti-CD16/CD32, clone 2.4G2, produced in house), prior to antibody staining. For
co-tetramer staining, cells were labelled with the lower afﬁnity CD1d–lipid
tetramer ﬁrst, washed twice and the second CD1d–lipid tetramer (i.e. CD1d–α-
GalCer) added together with surface antibodies. For TAME, anti-PE magnetic
beads (Miltenyl Biotech) were added to CD1d–α-GlcADAG-labelled cells and the
magnetically labelled fraction was isolated using LS columns (Miltenyl Biotech),
according to manufacturer’s instructions. Cells were analysed on a BD
LSRFortessa™ or BD LSR II™, or alternatively, singles cells were sorted on a BD
FACSAria III™ (Becton Dickinson) directly into 96-well plates. Samples were
analysed using FlowJo software (BD).
Glycolipids. α-GalCer (C26:0) was purchased from Alexis Biochemicals. GD3
(C26:0) was purchased from Matreya LLC. Sulfatide (C24:1) was purchased from
Avanti Polar Lipids. α-GlcADAG analogues were produced in house. α-GalCer
(C20:2), α-GlcCer (C20:2), were supplied by Prof. Gurdyal Besra (University of
Birmingham, UK). α-GalCer (C24:1 ‘PBS-44’) and Sphingomonas spp. GSL-1
(α-GlcACer C14:0) and GSL-1′ (α-GalACer C14:0) were provided by Prof. Paul
Savage (Brigham Young University, USA). Streptococcus pneumoniae α-GlcDAG
(C16:0/C18:1) and Borrelia burgdorferi α-GalDAG (C17:1/C16:0) were provided by
Dr. Petr Illarionov (from Gurdyal Besra’s Laboratory, University of Birmingham,
UK). Glycolipids were prepared in either tyloxapol-based detergent (0.5% or 0.05%
v/v tyloxapol in tris-buffered saline (TBS) pH 8, or Tween 20-based detergent
(0.5% Tween-20, 56 mg/mL sucrose, 7.5 mg/mL L-histidine in PBS). All glycolipids
were stored at −20 °C. Glycolipids were sonicated for ~30 min prior to each use.
Single cell nested multiplex PCR. cDNA from individually sorted CD1d
tetramer+ αβTCR+ cells was generated by the addition of 2 μl per well of buffer
containing SuperScript VILO (Invitrogen) and 0.1% Triton X-100 (Sigma) and
incubated according to manufacturer’s instructions. cDNA was ampliﬁed by two
rounds of multiplex nested PCR with a panel of Vα-speciﬁc and Vβ primers
(Supplementary Table 4)26,61 and GoTaq Master Mix (Promega). PCR products
were separated on a 1.5% agarose gel, puriﬁed and sequenced (Applied Genetics
Diagnostics, University of Melbourne).
Generation of TCR-transduced cell lines. T cell lines expressing αβ TCR were
generated by cloning full-length genes encoding α- and β-chains into a pMSCV-
IRES-GFP II (pMIG II) vector containing a cis-acting hydrolase element P2A-linked
gene system (Addgene plasmid # 52107). The generation of TCR-transduced mouse
NKT cell lines was performed similarly to what has been described for the gen-
eration of retrogenic mice62. Brieﬂy, HEK293T cells (maintained in house > 10
years) were transfected using FuGENE-6 transfection reagent (Promega) with
pMIGII expression vector containing both TCR α- and TCR β-chain-veriﬁed
sequences using vector-speciﬁc primers (Supplementary Table 4), pMIGII expres-
sion vector containing the CD3 subunits encoding sequences63, packaging vector
pEQ-Pam-3-E and packaging vector pVSV-G62. Retrovirus-containing supernatant
was collected every 12 h, ﬁltered in a 0.45 μm ﬁlter (Sartorius) and used to transduce
mouse BW5147.TCR α−β− thymoma cells (termed BW58—maintained in house >
10 years). The pMIG II, expression and packaging vectors were provided by Dr.
Dario Vignali (St. Jude’s Research Hospital, USA), and the CD3 expression vector
was provided by Prof. Stephen Turner (Monash University, Australia). BW58 cell
lines were cultured in complete Dulbecco’s modiﬁed Eagle medium (cDMEM,
Gibco) supplemented with 10% FBS (v/v), 15 mM HEPES (Gibco), 1 mM sodium
pyruvate (Gibco), 0.1 mM non-essential amino acids (Gibco), 50 μM β-
mercaptoethanol (Sigma), 100 U/mL penicillin (Invitrogen), 100 μg/mL strepto-
mycin (Invitrogen) and 2 mM L-glutamine (Invitrogen), at 37 °C, 5% CO2.
For plate bound activation assays, lipid-loaded CD1d was coated in 96-well ﬂat-
bottom plates (10 μg/ml) for 3 h at 37 °C. BW58 cell lines were co-cultured with
plate bound complex for 16 h in cDMEM. Cells were labelled with CD69 mAb to
asses CD69 upregulation (staining panel also included βTCR and 7AAD), and/or
culture supernatants were collected for IL-2 cytokine analysis using cytometric
bead array (CBA) ﬂex set for mice (BD Biosciences), according to the
manufacturer’s instructions.
Soluble TCR generation. Sequence-veriﬁed constructs encoding TCR α- or β-chains
in pET30 or pET28 (Supplementary Table 4) were expressed as inclusion body
protein (IBP) preparations using Escherichia coli BL-21 (DE3)pLysS and solubilised in
8M urea, 0.5mM ethylenediaminetetraacetic acid (EDTA) pH 8.0, 1mM dithio-
threitol (DTT) and 20mM Tris–HCl pH 8.0. Soluble TCR α- or β-chain IBPs were
injected into a refold buffer (containing 0.1M Tris, 2 mM EDTA, 0.4M arginine, 0.5
mM oxidised glutathione, 5mM reduced glutathione, and 5M urea, and a ﬁnal pH
8.5). Refolding occurred overnight with gentle stirring at 4 °C. Samples were dialysed
for 4 h into 100mM Urea, 10mM Tris–HCl pH 8.0 followed by two consecutive
dialysis into 10mM Tris–HCl at pH 8.0 (ﬁrst for 4 h and second overnight)31,50.
Refolded TCRs were puriﬁed by diethylaminoethanol (DEAE) sepharose anion
exchange, followed by Superdex-75 16/60 gel-ﬁltration (GE healthcare) and anion
exchange Mono Q 10/100 GL (GE healthcare). The molecular weight of soluble
refolded TCRs was validated by liquid chromatography (LC) electrospray ionisation
time of ﬂight (ESI-TOF) mass spectrometry (MS) (Agilent, Bio 21 institute).
Surface plasmon resonance. SPR experiments were performed on a BIAcore 3000
instrument at 25 °C in HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl). 1%
BSA was included in the buffer to prevent any non-speciﬁc binding. On average,
3000 response units (RUs) of biotinylated-CD1d were coupled onto a SAV (SAV)-
coated sensor chip. Biotin was passed over to block-free SAV sites. Serial dilutions
of soluble TCRs were passed over as analytes, and experiments were referenced
against an empty channel (SAV alone). Data were analysed using Scrubber Pro
(BioLogic Software) and BIAevaluation Version 3.1 (Biacore AB). The steady-state
dissociation rate (Kd; M values were derived manually from equilibrium analysis in
GraphPad Prism 5 using a one site-speciﬁc-binding model (1:1 Langmuir kinetic-
binding model).
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Crystallisation, structure determination and reﬁnement. The A11B8.2 TCR
(8–10 mg/mL) and A11B8.2–CD1d–α-GlcADAG ternary complex (5–7.5 mg/mL)
were crystallised in 10–20% PEG 3350/4% Tascimate, pH 4 and 15–25% PEG 1500/
10% succinate phosphate glycine, pH 6.8, respectively, using the hanging drop
vapour diffusion method. The crystals were ﬂash frozen and data were collected at
the MX1 and MX2 beamlines (Wavelength 0.9537 Å and 100 K) of the Australian
Synchrotron, respectively. The data for the A11B8.2 monomer and ternary com-
plex were processed with the XDS software64 and iMOSFLM 7.0.5/SCALA from
the CCP4 suite of programmes65, respectively. The TCR and the ternary complex
X-ray structures were determined by molecular replacement using the software
PHASER66. For the A11B8.2 TCR, the deposited structures (pdb code: 3QIB for the
variable domain Vα11 and pdb code: 3HE6 for the variable domain Vβ8.2) were
used as separate search ensembles while for the A11B8.2–CD1d–α-GlcADAG
structure, the structures of mouse CD1d minus the antigen (pdb code: 3HE6) and
the previously determined A11B8.2 structure were used. The initial experimental
phases showed an unbiased density for the headgroup of α-GlcADAG. The pro-
grammes BUSTER67 and COOT68 were used for reﬁnement and model building,
respectively. Subsequent reﬁnement cycles and model building resulted in ﬁnal
Rwork/Rfree values of 18.1%/21.9% (For A11B8.2) and 18.7%/24.6% (for
A11B8.2–CD1d–α-GlcADAG complex). The quality of both structures was vali-
dated at the Research Collaboratory for Structural Bioinformatics Protein Data
Bank (RCSB) Validation and Deposition Services. All presentations of molecular
graphics were created with the programme PyMOL69.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Atomic coordinates and structure factors of the A11B8.2 NKT TCR and A11B8.2 NKT
TCR–CD1d–α-GlcADAG ternary complex were deposited in the Protein Data Bank
(PDB) under the accession codes 6MRA [https://www.rcsb.org/structure/6MRA] and
6MSS [https://www.rcsb.org/structure/6MSS], respectively. All remaining data are
available within the article and its supplementary information ﬁles and from the
corresponding authors on request. Source data are provided as a Source Data ﬁle.
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